Comparing two ways to treat Crohn's disease if TNFi isn't working well
Treatments studied
Part of Digestive system clinical trials.
This trial tests if adding a low dose of a newer pill (upadacitinib) to your current TNF inhibitor (TNFi) works better than increasing the dose of your TNFi alone. It is for people with Crohn's disease who have had some improvement on their TNFi but still have active disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with Crohn's disease.
- You have been on a standard dose of a TNF inhibitor (like infliximab or adalimumab) for at least 12 weeks.
- Your Crohn's symptoms improved somewhat on the TNFi but you still have active disease (e.g., a CDAI score between 150 and 450, and signs of inflammation like ulcers on a scope or high calprotectin).
- You have not already tried a JAK inhibitor (like upadacitinib) before.
- You do not have a serious infection, severe bowel complications, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This trial tests a special diet (CDED) combined with anti-TNF medication (infliximab or adalimumab) to see if it's safe and works better for active Crohn's disease. It may help if you haven't used these drugs before and can follow the diet.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study compares two medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. Both are taken as injections or pills and aim to reduce inflammation and help you feel better.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.